Skip to main content

Adagio Medical Holdings, Inc.

For the period ended Dec 31, 2025. Filed Mar 27, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 27, 2026

ADGM$1.92Day change unavailableStored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​​​​
​ADAGIO MEDICAL HOLDINGS, INC.
​​​​
Date: March 26, 2026By:​/s/ Todd Usen
​​​Todd UsenChief Executive Officer

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Todd Usen and Deborah Kaster, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of Adagio Medical Holdings, Inc., and any or all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature​Title​Date
​​​​​
/s/ Todd Usen​Chief Executive Officer and Director(Principal Executive Officer)​March 26, 2026
Todd Usen​​​
​​​​​
/s/ Deborah Kaster​Chief Financial Officer(Principal Financial Officer and PrincipalAccounting Officer)​March 26, 2026
Deborah Kaster​​​
​​​​​
/s/ James L. Cox​Director​March 26, 2026
James L. Cox​​​​
​​​​​
/s/ Orly Mishan​Director​March 26, 2026
Orly Mishan​​​​
​​​​​
/s/ Keyvan Mirsaeedi-Farahani​Director​March 26, 2026
Keyvan Mirsaeedi-Farahani​​​​
​​​​​
/s/ Timothy Moran​Director​March 26, 2026
Timothy Moran​​​​
​​​​​
/s/ Sandra Gardiner​Director​March 26, 2026
Sandra Gardiner​​​​
​​​​​
/s/ Sean Salmon​Director​March 26, 2026
Sean Salmon​​​​
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.